KD6001

· Shanghai Kanda Biotechnology Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for KD6001, covering 2023-04-27 to 2024-01-10. Get the full timeline:

Most recent: Clinical Trial Update: KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors [Phase 1, Phase 2]

See pricing